137 related articles for article (PubMed ID: 24128601)
41. Diagnosis, management and screening of early localised prostate cancer.
Selley S; Donovan J; Faulkner A; Coast J; Gillatt D
Health Technol Assess; 1997; 1(2):i, 1-96. PubMed ID: 9414541
[TBL] [Abstract][Full Text] [Related]
42. Active Surveillance for Low-risk Prostate Cancer: Are All Criteria Similar?
Cimino S; Privitera S; Favilla V; Cantiello F; Manno S; Cicione A; Damiano R; Russo GI; Morgia G
Anticancer Agents Med Chem; 2018; 18(7):958-963. PubMed ID: 29692262
[TBL] [Abstract][Full Text] [Related]
43. Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?
Khan MA; Carter HB; Epstein JI; Miller MC; Landis P; Walsh PW; Partin AW; Veltri RW
J Urol; 2003 Dec; 170(6 Pt 1):2274-8. PubMed ID: 14634395
[TBL] [Abstract][Full Text] [Related]
44. Prostate-Specific Antigen-Based Screening for Prostate Cancer: Evidence Report and Systematic Review for the US Preventive Services Task Force.
Fenton JJ; Weyrich MS; Durbin S; Liu Y; Bang H; Melnikow J
JAMA; 2018 May; 319(18):1914-1931. PubMed ID: 29801018
[TBL] [Abstract][Full Text] [Related]
45. [Active surveillance for screen-detected prostate cancer - a strategy for the future?].
Weissbach L; Schaefer C
Aktuelle Urol; 2010 Jul; 41(4):239-44. PubMed ID: 20661840
[TBL] [Abstract][Full Text] [Related]
46. Active surveillance for localized prostate cancer: update of a prospective single-center cohort.
Thostrup M; Thomsen FB; Iversen P; Brasso K
Scand J Urol; 2018 Feb; 52(1):14-19. PubMed ID: 28958194
[TBL] [Abstract][Full Text] [Related]
47. Prospective Quality of Life in Men Choosing Active Surveillance Compared to Those Biopsied but not Diagnosed with Prostate Cancer.
Pham KN; Cullen J; Hurwitz LM; Wolff EM; Levie KE; Odem-Davis K; Banerji JS; Rosner IL; Brand TC; L'Esperance JO; Sterbis JR; Porter CR
J Urol; 2016 Aug; 196(2):392-8. PubMed ID: 26976206
[TBL] [Abstract][Full Text] [Related]
48. Generalizability of the Prostate Cancer Intervention Versus Observation Trial (PIVOT) Results to Contemporary North American Men with Prostate Cancer.
Dalela D; Karabon P; Sammon J; Sood A; Löppenberg B; Trinh QD; Menon M; Abdollah F
Eur Urol; 2017 Apr; 71(4):511-514. PubMed ID: 27638094
[TBL] [Abstract][Full Text] [Related]
49. Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.
Gnanapragasam VJ; Lophatananon A; Wright KA; Muir KR; Gavin A; Greenberg DC
PLoS Med; 2016 Aug; 13(8):e1002063. PubMed ID: 27483464
[TBL] [Abstract][Full Text] [Related]
50. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
Leibovici D; Lindner A; Stay K; Zisman A
Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
[TBL] [Abstract][Full Text] [Related]
51. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
Klotz L
Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
[TBL] [Abstract][Full Text] [Related]
52. Selecting men diagnosed with prostate cancer for active surveillance using a risk calculator: a prospective impact study.
van Vugt HA; Roobol MJ; van der Poel HG; van Muilekom EH; Busstra M; Kil P; Oomens EH; Leliveld A; Bangma CH; Korfage I; Steyerberg EW
BJU Int; 2012 Jul; 110(2):180-7. PubMed ID: 22112199
[TBL] [Abstract][Full Text] [Related]
53. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
[TBL] [Abstract][Full Text] [Related]
54. Expectant management for men with early stage prostate cancer.
Filson CP; Marks LS; Litwin MS
CA Cancer J Clin; 2015; 65(4):265-82. PubMed ID: 25958817
[TBL] [Abstract][Full Text] [Related]
55. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
56. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
[TBL] [Abstract][Full Text] [Related]
57. Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance.
Josefsson A; Wikström P; Egevad L; Granfors T; Karlberg L; Stattin P; Bergh A
Scand J Urol Nephrol; 2012 Aug; 46(4):247-57. PubMed ID: 22452635
[TBL] [Abstract][Full Text] [Related]
58. Age remains the major predictor of curative treatment non-receipt for localised prostate cancer: a population-based study.
de Camargo Cancela M; Comber H; Sharp L
Br J Cancer; 2013 Jul; 109(1):272-9. PubMed ID: 23722470
[TBL] [Abstract][Full Text] [Related]
59. Determinants for choosing and adhering to active surveillance for localised prostate cancer: a nationwide population-based study.
Bergengren O; Garmo H; Bratt O; Holmberg L; Johansson E; Bill-Axelson A
BMJ Open; 2019 Dec; 9(12):e033944. PubMed ID: 31874896
[TBL] [Abstract][Full Text] [Related]
60. The role of active surveillance in the management of prostate cancer.
Fung-Kee-Fung SD; Porten SP; Meng MV; Kuettel M
J Natl Compr Canc Netw; 2013 Feb; 11(2):183-7. PubMed ID: 23411385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
